COVID-19 恢复期血浆：从捐献到治疗 - 系统评价和单中心经验。
COVID-19 Convalescent Plasma: from donation to treatment - A Systematic Review & Single Center Experience.
机构信息
Medical Student, University of Missouri-Columbia, Columbia, Missouri.
Assistant Professor of Clinical Medicine, Medical Director, Outpatient Parenteral Antimicrobial Therapy (OPAT) and Vascular Access, and Medical Director, HIV/AIDS Program, University of Missouri-Columbia, Columbia, Missouri.
出版信息
Mo Med. 2021 Jan-Feb;118(1):74-80.
Abstract
Convalescent plasma is an old treatment for a new disease. The coronavirus disease 2019 (COVID-19) pandemic caused the analysis of convalescent plasma to reemerge as a possible treatment. First, a systematic review summarizes the available research examining the use of convalescent plasma for the treatment of patients with COVID-19. Second, we describe our experience in establishing a single-center convalescent plasma donation program.
摘要
恢复期血浆是一种古老的治疗新疾病的方法。2019 年冠状病毒病（COVID-19）大流行促使对恢复期血浆治疗的分析重新成为一种可能的治疗方法。首先，系统评价总结了现有研究，这些研究检查了恢复期血浆治疗 COVID-19 患者的用途。其次，我们描述了在建立单中心恢复期血浆捐献计划方面的经验。
相似文献
1
COVID-19 Convalescent Plasma: from donation to treatment - A Systematic Review & Single Center Experience.
Mo Med. 2021 Jan-Feb;118(1):74-80.
2
Motivators of and barriers to becoming a COVID-19 convalescent plasma donor: A survey study.
Transfus Med. 2021 Jun;31(3):176-185. doi: 10.1111/tme.12753. Epub 2020 Dec 27.
3
Deterrents in recruitment of COVID-19 convalescent plasma donors: Experience from a hospital-based blood centre in India.
Transfus Med. 2021 Jun;31(3):149-154. doi: 10.1111/tme.12768. Epub 2021 Mar 21.
4
Longitudinal analysis of SARS-CoV-2 antibodies in 8000 U.S. first-time convalescent plasma donations.
Transfusion. 2021 Apr;61(4):1141-1147. doi: 10.1111/trf.16291. Epub 2021 Feb 22.
5
A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China.
Med Sci Monit. 2020 Dec 2;26:e928755. doi: 10.12659/MSM.928755.
6
The demographic and serological characteristics of COVID-19 convalescent plasma donors: Identification of basic criteria for optimal donor selection.
Transfus Apher Sci. 2022 Apr;61(2):103302. doi: 10.1016/j.transci.2021.103302. Epub 2021 Oct 29.
7
Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China.
Transfusion. 2020 Aug;60(8):1773-1777. doi: 10.1111/trf.15921. Epub 2020 Jul 31.
8
Donor tolerability of convalescent plasma donation.
J Clin Apher. 2021 Jun;36(3):429-436. doi: 10.1002/jca.21882. Epub 2021 Feb 15.
9
Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes.
Hum Immunol. 2021 Apr;82(4):255-263. doi: 10.1016/j.humimm.2021.02.007. Epub 2021 Feb 16.
10
Constraints and challenges in convalescent plasma collection amidst the Covid 19 pandemic- strategies and recommendations to overcome these.
Transfus Clin Biol. 2021 May;28(2):175-179. doi: 10.1016/j.tracli.2021.02.003. Epub 2021 Mar 4.
引用本文的文献
1
Factors influencing plasma donation behavior of COVID-19 recovered patients in Bangladesh: A pilot study.
Health Sci Rep. 2022 Dec 2;6(1):e974. doi: 10.1002/hsr2.974. eCollection 2023 Jan.
2
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials.
BMC Infect Dis. 2021 Nov 20;21(1):1170. doi: 10.1186/s12879-021-06829-7.
3
Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews.
Diagnostics (Basel). 2021 Sep 11;11(9):1663. doi: 10.3390/diagnostics11091663.
本文引用的文献
1
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.
Science. 2020 Aug 7;369(6504):643-650. doi: 10.1126/science.abc5902. Epub 2020 Jun 15.
2
Early safety indicators of COVID-19 convalescent plasma in 5000 patients.
J Clin Invest. 2020 Sep 1;130(9):4791-4797. doi: 10.1172/JCI140200.
3
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.
JAMA. 2020 Aug 4;324(5):460-470. doi: 10.1001/jama.2020.10044.
4
How did we rapidly implement a convalescent plasma program?
Transfusion. 2020 Jul;60(7):1348-1355. doi: 10.1111/trf.15910. Epub 2020 Jun 11.
5
Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis.
CMAJ. 2020 Jul 6;192(27):E745-E755. doi: 10.1503/cmaj.200642. Epub 2020 May 22.
6
Gender Differences in Patients With COVID-19: Focus on Severity and Mortality.
Front Public Health. 2020 Apr 29;8:152. doi: 10.3389/fpubh.2020.00152. eCollection 2020.
7
Convalescent plasma in Covid-19: Possible mechanisms of action.
Autoimmun Rev. 2020 Jul;19(7):102554. doi: 10.1016/j.autrev.2020.102554. Epub 2020 May 5.
8
Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019.
J Infect Dis. 2020 Jun 16;222(1):38-43. doi: 10.1093/infdis/jiaa228.
9
Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.
J Med Virol. 2020 Oct;92(10):1890-1901. doi: 10.1002/jmv.25882. Epub 2020 Jun 29.
10
Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China.
JAMA. 2020 May 19;323(19):1915-1923. doi: 10.1001/jama.2020.6130.
Zotero 插件